PL1631312T3 - Kompozycje i sposoby terapii choroby zapalenia jelit - Google Patents

Kompozycje i sposoby terapii choroby zapalenia jelit

Info

Publication number
PL1631312T3
PL1631312T3 PL04750581T PL04750581T PL1631312T3 PL 1631312 T3 PL1631312 T3 PL 1631312T3 PL 04750581 T PL04750581 T PL 04750581T PL 04750581 T PL04750581 T PL 04750581T PL 1631312 T3 PL1631312 T3 PL 1631312T3
Authority
PL
Poland
Prior art keywords
compositions
therapy
methods
inflammatory bowel
bowel disease
Prior art date
Application number
PL04750581T
Other languages
English (en)
Inventor
Lesley B Pickford
Christopher R Bebbington
Geoffrey T Yarranton
David King
Original Assignee
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Llc filed Critical Squibb & Sons Llc
Publication of PL1631312T3 publication Critical patent/PL1631312T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04750581T 2003-04-23 2004-04-23 Kompozycje i sposoby terapii choroby zapalenia jelit PL1631312T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46515503P 2003-04-23 2003-04-23
EP04750581A EP1631312B1 (en) 2003-04-23 2004-04-23 Compositions and methods for the therapy of inflammatory bowel disease
PCT/US2004/012651 WO2004093908A2 (en) 2003-04-23 2004-04-23 Compositions and methods for the therapy of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
PL1631312T3 true PL1631312T3 (pl) 2009-02-27

Family

ID=33311000

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04750581T PL1631312T3 (pl) 2003-04-23 2004-04-23 Kompozycje i sposoby terapii choroby zapalenia jelit

Country Status (21)

Country Link
US (2) US7939076B2 (pl)
EP (1) EP1631312B1 (pl)
JP (1) JP4628357B2 (pl)
KR (1) KR100817351B1 (pl)
CN (2) CN101318019B (pl)
AT (1) ATE407698T1 (pl)
AU (1) AU2004232362C1 (pl)
BR (1) BRPI0410495A (pl)
CA (2) CA2823468A1 (pl)
DE (1) DE602004016499D1 (pl)
DK (1) DK1631312T3 (pl)
ES (1) ES2313039T3 (pl)
IL (1) IL171356A (pl)
MX (1) MXPA05011409A (pl)
NZ (1) NZ542866A (pl)
PL (1) PL1631312T3 (pl)
PT (1) PT1631312E (pl)
SG (1) SG173919A1 (pl)
SI (1) SI1631312T1 (pl)
WO (1) WO2004093908A2 (pl)
ZA (1) ZA200508390B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
AU2004232362C1 (en) 2003-04-23 2008-05-29 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR101166901B1 (ko) 2010-04-16 2012-07-19 송영완 임플란트용 주입기
JP2013528622A (ja) * 2010-06-04 2013-07-11 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 炎症性障害の処置
SG187201A1 (en) 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
EP3179985A1 (en) * 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN108409862B (zh) 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
KR102711685B1 (ko) * 2017-06-02 2024-09-27 굿것 에스.엘. 장내 세균 불균형의 치료에 사용하기 위한 포도 껍질
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
CN112056275B (zh) * 2020-09-27 2022-05-10 澎立生物医药技术（上海）有限公司 一种肠粘膜炎动物模型及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
IL88377A (en) 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DK0601052T3 (da) 1991-08-30 1996-11-18 Genentech Inc Terapeutisk fremgangsmåde til behandling af IDDM
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
DK0695189T3 (da) 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
EP0725654A1 (en) * 1993-09-17 1996-08-14 Laboratoire Europeen De Biotechnologie S.A. Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
AU1289595A (en) 1993-11-15 1995-06-06 Cell Therapeutics, Inc. Method for selectively inhibiting il-2 signal transduction
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
ES2383002T3 (es) 1998-01-30 2012-06-15 Allertein Therapeutics, Llc Prueba pronóstica de alergia
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4156324B2 (ja) 2002-09-30 2008-09-24 ローム株式会社 直流−交流変換装置、及び交流電力供給方法
JP2007525458A (ja) 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
AU2004232362C1 (en) 2003-04-23 2008-05-29 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
KR101225299B1 (ko) * 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses

Also Published As

Publication number Publication date
AU2004232362C1 (en) 2008-05-29
AU2004232362A1 (en) 2004-11-04
US7939076B2 (en) 2011-05-10
KR100817351B1 (ko) 2008-03-26
WO2004093908A2 (en) 2004-11-04
HK1082200A1 (en) 2006-06-02
US20050152901A1 (en) 2005-07-14
SI1631312T1 (sl) 2009-02-28
JP2006524703A (ja) 2006-11-02
PT1631312E (pt) 2008-12-22
IL171356A (en) 2010-11-30
MXPA05011409A (es) 2005-12-12
US20110165158A1 (en) 2011-07-07
AU2004232362B2 (en) 2007-09-06
ZA200508390B (en) 2006-06-28
CA2522957C (en) 2013-10-22
ATE407698T1 (de) 2008-09-15
ES2313039T3 (es) 2009-03-01
SG173919A1 (en) 2011-09-29
US8828393B2 (en) 2014-09-09
CA2522957A1 (en) 2004-11-04
KR20060015531A (ko) 2006-02-17
EP1631312B1 (en) 2008-09-10
WO2004093908A3 (en) 2005-06-02
DE602004016499D1 (de) 2008-10-23
CN101318019A (zh) 2008-12-10
BRPI0410495A (pt) 2006-06-13
CN100409897C (zh) 2008-08-13
NZ542866A (en) 2009-07-31
CA2823468A1 (en) 2004-11-04
JP4628357B2 (ja) 2011-02-09
EP1631312A2 (en) 2006-03-08
DK1631312T3 (da) 2009-01-19
CN101318019B (zh) 2012-08-29
CN1777444A (zh) 2006-05-24

Similar Documents

Publication Publication Date Title
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
ZA200701656B (en) Humanized anti-cment antagonists
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
TW200740844A (en) Novel MAdCAM antibodies
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
IL187079A0 (en) An oligoadenylate synthetase 1 protein, therapeutic compositions containing the same and screening methods
WO2008011710A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
MY142798A (en) Methods for preventing glyconoylation of proteins